Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market
Rising Number of Cancer Cases and Patients Undergoing Chemotherapy to Boost the Growth of Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market
Fact.MR's global chemotherapy-induced nausea and vomiting (CINV) treatment industry analysis predicts the market to attain a valuation of US$ 5.7 Bn by the end of the decade, which will be 1.5X its worth at present. This research survey forecasts the market to expand at a significant CAGR of around 6% through 2031, with the U.S. slated to account for over 85% market share in North America.
Key Analysis Offered in Chemotherapy-Induced Nausea and Vomiting Treatment Industry Survey
- Market Estimates and Forecasts 2016-2031
- Key Drivers and Restraints Impacting Market Growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Market Share Analysis by Key Players
- Key Product Innovations and Regulatory Scenario
- COVID-19 Impact on Demand for Chemotherapy Induced Nausea and Vomiting Treatment and How to Navigate
- Recommendation on Key Winning Strategies
Demand Analysis of CINV Treatment from 2016 to 2020 Compared to Market Outlook for 2021-2031
According to Fact.MR, a market research and competitive intelligence provider, the global chemotherapy-induced nausea and vomiting therapeutics market is valued at US$ 5.7 Bn in 2021 and is slated to expand at a CAGR of 6% over the decade.
Rising prevalence of cancer, increasing number of patients undergoing chemotherapy & radiotherapy treatments, increasing compliance to chemotherapy drugs due to varied treatment options, and availability of combination therapies are driving demand for chemotherapy-induced nausea and vomiting (CINV) treatment drugs.
Growth of the CINV treatment market in 2021 is being further augmented by the introduction of new products. Innovations in drug delivery and development and shift toward biologics are also expected to boost the growth of the global chemotherapy-induced nausea and vomiting (CINV) drugs market.
How is Rising Prevalence of Cancer and Increasing Number of Patients Undergoing Chemotherapy Treatments Impacting Market Growth?
Rising prevalence of cancer across the world and growing number of patients undergoing chemotherapy have increased the number of side-effects associated with chemotherapy, thereby driving demand for chemotherapy-induced nausea and vomiting treatment.
For instance, as per GLOBOCAN, in 2020, around 19.3 million new cancer cases and around 10 million people died due to cancer. Moreover, it was expected that around 28.4 million new cancer cases may be diagnosed by 2040.
Similarly, around 4 million cancer patients undergo chemotherapy or radiotherapy annually, which is one the most widely used treatments for cancer. An approximately 70% - 80% of patients undergoing chemotherapy treatment leads to CINV as an adverse effect.
Avail customized purchase options for your needs
What are the Key Opportunities for CINV Treatment Product Manufacturers?
There are several approved drugs available in the market for the treatment of chemotherapy-induced nausea and vomiting. The types of approved medications used to treat CINV include 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, and cannabinoids.
Most patients adopt these drugs for managing chemotherapy-induced nausea and vomiting, manufactured by Kyowa Kirin, Inc., Pfizer Inc., and Merck & Co., Inc. among others. These pharmaceutical companies have a global presence, which enables them to promote and distribute their drugs throughout the globe. Moreover, many branded drugs are easily available in the market for chemotherapy-induced nausea and vomiting corticosteroids therapy.
It has been estimated that pharmaceutical companies invest around 10% of their total turnover in new R&D initiatives, while the cost of R&D has increased by over 150% over the past decade. Hence, identification of new drug combinations beforehand is vital.
Manufacturers are also trying to develop generic competencies to validate bioequivalence to reference prescription drugs in the CINV market, as several key drugs no longer benefit from intellectual property protection.
Availability of a large number of approved drugs for the treatment of chemotherapy-induced nausea and vomiting in retail pharmacies and high investments in R&D by pharmaceuticals companies have created tremendous opportunities for the growth of the market.
What is Restraining Demand for CINV Treatment?
Despite a significant amount of research & development of antiemetic agents, management of chemotherapy-induced nausea and vomiting remains a great challenge. Poorly managed CINV results in high economic burden and decreased quality of life.
With many needs waiting to be adequately addressed, such as controlling non-acute chemotherapy-induced nausea and vomiting, developing appropriate CINV treatment protocols for multiple-day chemotherapy patients and providing options for those prone to CINV despite treatment is important. Further research is required to optimize CINV management for patients.
Moreover, In North America and Europe, regulations for cancer drug is quite complex. Key players in the market are committed to providing quality products and drugs, which must comply with the U.S. Food and Drug Administration (FDA) and other regulations by government and non-government bodies.
According to the European Society for Medical Oncology and European Association for Palliative Care national representatives, various patients in Europe are unable to receive adequate treatment for CINV due to excessive regulatory restrictions on the availability and accessibility of drugs to ease this side-effect. Several factors, particularly loss of brand exclusivity for various generic drugs, are expected to shrink the market in the U.S., U.K., and some other parts of Europe.
Lack of management of chemotherapy-induced nausea and vomiting treatment, loss of brands exclusivity of various generic drugs, and regulatory barriers are hindering market growth. More restrictive healthcare reimbursement policies and increased competition are also expected to contribute to the decline.
An Adaptive Approach to Modern-day Research Needs
How Lucrative is the Opportunity for CINV Drug Manufacturers in the U.S.?
The U.S. is estimated to account for nearly 86% share in 2021 and represents the largest regional market in the world. Leading pharmaceutical companies in the country are focusing on the development of oral chemotherapy-induced nausea and vomiting treatment drugs and intravenous CINV treatment drugs for treatment.
Moreover, few manufacturers are solely focusing on the development of drugs for the treatment of CINV with minimum side-effects. Besides, several new and improved drugs for chemotherapy are been launched in the market.
- For instance, in August 2016, Heron Therapeutics received U.S. FDA approval for SUSTOL, an extended-release injection of granisetron for the prevention of CINV.
- In October 2017, TESARO Inc. received U.S. FDA approval of VARUBI IV for delayed CINV.
Thus, increasing spending by leading pharmaceutical companies for product launch and development of drugs for treatment of chemotherapy-induced nausea in cancer patients is driving the U.S. chemotherapy-induced nausea and vomiting therapeutics market.
What are the Key Factors Enabling Growth of the Market for Chemotherapy Induced Nausea and Vomiting Treatment in Germany?
Germany accounted for over 17% market share of Europe in 2020. The prevention and treatment of chemotherapy-induced nausea and vomiting in adults is a prime focus by people in Germany. Key players are focusing on strategizing opportunities for chemotherapy-induced nausea and vomiting (CINV) drugs in Germany.
How is Increased Focus on Maintaining Superior Quality of Life Aiding Market Expansion in the U.K?
The U.K. CINV therapy market is projected to expand at around 6.4% CAGR and account for nearly 20% of the European market.
Increase in the number of patients undergoing chemotherapy and radiation therapy, high per capita healthcare expenditure, well-established healthcare facilities, and favorable medical reimbursement policies have added to the growth of the U.K. market.
Why is There a Surge in the Adoption of CINV Treatment in China?
Growth in East Asia is expected to happen at a faster speed. The World Health Organization reported that, in 2020, around 4.5 Mn new cancer cases were diagnosed in China. The incidence rate of obesity and hormonal exposure-related cancers, such as breast cancer in females and lifestyle change-related cancer, such as prostate cancer in males, showed a rising trend in China.
Based on results revealed in the Global Burden of Disease Study, cancer was the leading cause of death in the country in 2020. These figures are indicative of opportunities for wider penetration in China, consequently in South Asia.
An increase in incidence of cancer, growing preference for chemotherapy, and increasing awareness related to CINV in Asian countries such as China is another key factor driving rapid growth of the market.
Why is Demand for 5-HT3 Receptor Antagonists on the Rise?
5-HT3 receptor antagonists are expected to account for the second-largest market share of 42%.
Increased R&D investments by pharmaceutical and biotechnology companies for the development of highly effective and efficient 5-HT3 receptor antagonist drugs with minimum side-effects is increasing demand for 5-HT3 receptor antagonists for chemotherapy-induced nausea and vomiting treatment.
Why are Injectables the Preferred form for CINV Treatment?
Injectables are the most preferred form for CINV treatment due to the maximum efficacy that they provide. The segment is projected to expand at a CAGR of 6.4% over the next ten years.
What is the Scope of Growth for Hospitals for CINV Treatment?
Hospitals for chemotherapy-induced nausea and vomiting treatment are expected to witness significant growth at 4.5% CAGR.
The ability of hospitals to manage a high patient count undergoing cancer chemotherapy is a key factor fueling the growth of this segment. Further, hospitals are well-equipped with advanced technological instruments and facilities that provide more effective treatment.
Interested to Procure The Data
The global CINV treatment market is marked by the presence of emerging as well as established players. Rising need for chemotherapy-induced nausea and vomiting treatment has motivated key players to launch new and innovative products in the market.
Leading manufacturers of medications for the treatment of chemotherapy-induced nausea and vomiting are focusing on acquisitions to expand their product portfolios and gain maximum market share.
- In January 2019, GSK completed the acquisition of TESARO Inc., an oncology-focused biopharmaceutical company, for an aggregate cash consideration of approximately US$ 5.1 billion.
- In July 2019, Pfizer Inc. acquired U.S.-based pharmaceutical company Array BioPharma Inc. This acquisition is estimated to strengthen the innovative biopharmaceutical business and assist in meeting the unmet medical needs of diseases such as cancer and other rare diseases.
CINV Treatment Market Report Scope
Market size value in 2021
USD 5.7 Billion
Market forecast value in 2031
USD 10.2 Billion
CAGR of 6% from 2021 to 2031
Historical Data Available for
|USD Million for Value|
Key Regions Covered
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Available upon Request
Segments as per Global CINV Treatment Industry Research
- Transdermal Patches
By Drug Class
- 5-HT3 Receptor Antagonists
- Neurokinin-1 Receptor Antagonists
By Emetogenik Risk
- Highly Emetogenic Chemotherapy (HEC)
- Moderately Emetogenic Chemotherapy (MEC)
- Low Emetogenic Chemotherapy (LEC)
By Distribution Channel
- CINV Hospitals
- Cancer Research Institute
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- FAQs -
At present, the global chemotherapy-induced nausea and vomiting treatment market is worth US$ 5.7 Bn.
The market is expected to top US$ 10.2 Bn by the end of 2031, with sales revenue expected to register a CAGR of 6% over the same period.
From 2016-2020, the market expanded at the rate of 4.7%, owing to rise in incidence of cancer and increased number of patients undergoing chemotherapy.
Leading manufacturers are focusing on acquisitions to expand their product portfolio and gain maximum market share.
The U.S., Germany, France, China, and the U.K. are expected to drive increased demand for CINV treatment over the next ten years.
North America is a key market for sales of chemotherapy-induced nausea and vomiting (CINV) treatment drugs, with the U.S. expected to account for 85% market share through 2031.
Demand for CINV treatment is expected to register a growth rate of 6% in Europe.
The market in Japan will offer lucrative growth opportunities and is expected to exhibit a CAGR of 5.5%, while South Korea holds a revenue share of 18% with growing solutions for chemotherapy-related nausea and vomiting.
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.